secwatch.observer — SEC 8-K summary
======================================

Issuer:     SPRUCE BIOSCIENCES, INC. (SPRB)
CIK:        0001683553
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0000950170-23-021979
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spruce Biosciences Q1 net loss $12.8M; CAH trials near enrollment goals; PCOS study topline Q3 2023
--------------------------------------------------------------------------------

- Cash and investments $118.6M as of March 31, 2023; with Kaken $15M upfront, runway into H1 2025.
- Collaboration revenue $2.0M (Kaken deal); R&D $11.7M; net loss $12.8M vs $11.8M YoY.
- CAHmelia-204 (adult CAH) 50% enrolled; CAHmelia-203 approaching 75% enrollment.
- P.O.W.E.R. PCOS Phase 2 fully enrolled (27 subjects); topline results expected Q3 2023.
- Appointed Mo Noursalehi, Ph.D., as SVP of Biometrics; completed $53.6M private placement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1683553/000095017023021979/0000950170-23-021979-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1683553/000095017023021979/sprb-20230515.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-021979

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer